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Objective: The objective of this study was to determine the effective dose of an amino acid 
mixture comprising arginine, alanine, and phenylalanine combined with physical activity pro-
motion in reducing abdominal fat among overweight adults.
Methods: A 12-week randomized, double-blind, placebo-controlled, dose-ranging, pilot trial was 
conducted in Mito, Japan, from January through April 2016, and the data were analyzed from May 
through November 2016. The study participants were 35 overweight adults, aged 20–64 years, 
with no regular exercise habit. Participants were randomly assigned to high-dose (3,000 mg/d, 
n=9), medium-dose (1,500 mg/d, n=9), low-dose (750 mg/d, n=8), or placebo (0 mg/d, n=9) 
groups, and the test beverage containing the amino acid mixture or placebo was administered 
for 12 weeks. All participants maintained a physically active lifestyle during the study period 
through monthly physical activity promotion sessions and smartphone-based self-monitoring 
with wearable trackers. Primary outcomes were changes in abdominal total, subcutaneous, and 
visceral fat areas, assessed by computed tomography.
Results: Of the 35 enrolled participants, 32 completed the 12-week follow-up visit. The inten-
tion-to-treat analysis revealed that the changes in abdominal total fat area were −14.6 cm2 (95% 
confidence interval [CI], −39.6 cm2 to 10.4 cm2), −25.3 cm2 (95% CI, −71.0 cm2 to 20.3 cm2), 
−23.2 cm2 (95% CI, −48.0 cm2 to 1.6 cm2), and −12.5 cm2 (95% CI, −29.1 cm2 to 4.0 cm2) in 
the high-dose, medium-dose, low-dose, and placebo groups, respectively. Similar results were 
obtained for visceral and subcutaneous fat areas. No study-related adverse events were reported.
Conclusion: Compared with placebo, a medium or low dose of the amino acid mixture may 
facilitate abdominal fat reduction among overweight adults. A larger randomized trial with suf-
ficient statistical power should be implemented to validate the effectiveness of this supplement.
Keywords: amino acid mixture, dose–response relationship, physical activity promotion, 
abdominal fat
Introduction
As eating habits and lifestyle become more Westernized in Japan, the proportion of 
obese (defined as body mass index [BMI] ≥25 kg/m2) Japanese has been increasing 
steadily in recent decades.1 According to the National Health and Nutrition Survey 
conducted in 2015,2 the prevalence of overweight or obese Japanese adults is 29.5% 
in males and 19.2% in females. Furthermore, among Japanese adults with abdominal 
obesity, aged 40–74 years, 20 million are estimated to have metabolic abnormalities 
such as hyperglycemia, dyslipidemia, and hypertension.3 This suggests that Japanese 
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individuals are susceptible to cardiovascular diseases or other 
serious complications at even mild levels of overweight.
To prevent and/or mitigate these concerns, weight loss 
through dietary restriction and regular exercise is considered 
the best available non-surgical, non-pharmacologic treatment 
strategy.4 Moreover, additive or synergetic effects of diet and 
exercise have received much attention in recent years.5,6 Our 
team has been studying the effects of amino acids combined 
with exercise on fat oxidation for the past two decades.7–14 
We demonstrated that a 12-week administration of a mix-
ture of 17 amino acids combined with regular exercise 
increased aerobic fitness and reduced abdominal visceral 
fat in sedentary older women.12 We also reported that acute 
administration of different compositions of 17 amino acids 
significantly increased maximal blood levels of glycerol and 
acetoacetic acid during exercise.13 Recently, we focused on 
arginine, alanine, and phenylalanine, which are involved in 
glucagon synthesis and secretion when administered acutely. 
We also confirmed that a single session of aerobic exercise 
combined with an oral arginine, alanine, and phenylalanine 
mixture (A-mix) increased blood glycerol levels and ketone 
body levels in humans, compared with placebo.14 These find-
ings suggest a lipolytic effect during exercise attributable to 
ingesting the A-mix.
To our knowledge, no study has evaluated the long-term 
effectiveness of A-mix ingestion for overweight or obese 
individuals, and the effective dose of the mixture is unknown. 
Therefore, the objective of this 12-week pilot trial was to 
determine the effective dose of oral A-mix, along with its 
effects when combined with physical activity on abdominal 
fat reduction in overweight adults aged 20–64 years. The 
findings from this pilot trial will allow us to design a future 
trial with a larger sample size to confirm the effectiveness 
of combining A-mix ingestion with physical activity in 
overweight adults.
Methods
Trial design
This study was a pilot placebo-controlled, double-blind, 
parallel-group, randomized trial; the trial was conducted at a 
single site in Mito, Japan, from January through April 2016, 
and the data were analyzed from May through November 
2016. The study protocol was approved by the Institutional 
Review Board, University of Tsukuba Faculty of Medicine, 
and the Meiji Institutional Review Board. Each participant 
provided written informed consent before randomization. The 
protocol was registered in the UMIN Clinical Trials Registry 
(UMIN000019870) on November 15, 2015. This article fully 
complies with the Consolidated Standards of Reporting Trials 
(CONSORT) 2010 guideline.15 A data-monitoring committee 
assured accuracy of data collection and inputs.
Participants
Participants were recruited via advertisements posted in local 
newspapers and volunteer databases associated with two 
contract research organizations. The inclusion criteria were 
overweight (BMI ≥25 but <30 kg/m2) adults aged 20–64 years 
old without regular exercise habits. A regular exercise habit 
was defined as engaging in at least 30 min of exercise twice 
a week for more than 1 year, according to the criteria of the 
National Health and Nutrition Survey.2 The exclusion crite-
ria were individuals with a history or current condition of 
severe diseases, heavy drinkers (≥40 g of ethanol/d), heavy 
smokers (≥40 cigarettes/d), those with extremely irregular 
eating patterns due to shift work or late-night work, those who 
were pregnant or breastfeeding or wished to become preg-
nant during the study period, those who regularly consumed 
functional foods or nutritional supplements or who had taken 
them over the past 6 months, patients with phenylketonuria 
or hyperphenylalaninemia, those who were enrolled in other 
clinical trials, those who had participated in other clinical 
trials over the past 6 months, and those who were judged 
ineligible by the study physician (HK) due to abnormal blood 
and urine parameters or other reasons.
randomization and blinding
After stratifying by sex, eligible participants were random-
ized to the high-dose, medium-dose, low-dose, or placebo 
group, with an allocation ratio of 1:1:1:1. A statistician who 
had no contact with the participants and staff members gener-
ated a random number sequence using a validated computer 
program. The random sequence was kept by a designated 
person who was in charge of shipping the test beverages 
to participants, but was not involved in the design, recruit-
ment, assessment, intervention, or analysis. Participants and 
investigators were blinded to the group assignment. The ran-
domization code was opened after the dataset was carefully 
checked, cleaned, and fixed.
interventions
The test item was a 500-mL PET bottle beverage, containing 
3,000 mg, 1,500 mg, or 750 mg A-mix for the high-dose, 
medium-dose, and low-dose groups, respectively; the pla-
cebo group received a beverage containing 0 mg A-mix. We 
recently found increased levels of blood glycerol and ketone 
body concentrations following a single session of aerobic 
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exercise after ingesting 3,000 mg of A-mix.14 Based on this 
finding, we set 3,000 mg/d as the upper limit and geometri-
cally allocated the remaining doses at 1,500 mg, 750 mg, and 
0 mg. The test beverages had identical appearance and similar 
sensory characteristics and were, therefore, indistinguish-
able from each other. The A-mix contained 42% mol/mol of 
phenylalanine, 38% mol/mol of alanine, and 20% mol/mol 
of arginine. The calorie counts per bottle in the test beverages 
were 26 kcal, 20 kcal, 17 kcal, and 14 kcal, for the high-dose, 
medium-dose, low-dose, and placebo groups, respectively. 
None of the test beverages contained caffeine. The designated 
person shipped the test beverages to participants based on 
group assignment. Participants were instructed to keep the 
test beverages away from direct sunlight, high temperature, 
and high humidity, and to consume one bottle per day before 
and during moderate or vigorous physical activity under 
free-living conditions.
Irrespective of group assignment, all participants 
received a physical activity promotion program throughout 
the 12-week intervention period. The intervention program 
comprised a combination of monthly group-based physical 
activity classes with individualized counseling and a remote 
coaching program for physical activity promotion via smart-
phone apps. Participants were encouraged to increase 1,000 
steps/d or more from their baseline step counts according 
to the recent physical activity guideline in Japan.16,17 Each 
group-based physical activity class began with 90-min group-
based physical activity sessions, which included walking, 
muscle-strengthening activity, and stretching, and was fol-
lowed by 30-min individualized counseling sessions regard-
ing the timing of daily physical activity and test beverage 
ingestion. Experienced interventionists led the individualized 
counseling sessions while reviewing participants’ recent 
step counts, body weight, test beverage ingestion, physical 
condition, medication use, sleep patterns, dietary habits, 
and exercise, all of which were recorded in diaries. In the 
remote coaching program, all participants were provided 
with a wristband-type activity tracker (Fitbit Flex; Fitbit, 
San Francisco, CA, USA) and were instructed to monitor 
daily step counts, to record their body weight using a digital 
scale at home, and to transmit the information through a 
semi-customized smartphone app (HealthPlayer; Practechs, 
Tokyo, Japan). The interventionists reviewed the uploaded 
information and emailed the participants weekly to encour-
age physical activity. The smartphone app also displayed the 
weekly rankings of each participant’s step counts up to the 
top tenth, which was used as a motivation tool for promoting 
physical activity under unsupervised home settings. To avoid 
the confounding effects of lifestyle changes, participants were 
instructed to consume well-balanced meals three times per 
day according to the Japanese Food Guide Spinning Top18 
and to refrain from excessively strenuous exercise, binge eat-
ing, severe energy restriction, or consumption of nutritional 
supplements, functional foods, and over-the-counter drugs 
that could potentially affect study outcomes. 
Measurements
All study outcomes were measured at baseline and during a 
12-week follow-up visit by trained staff members who were 
blinded to the group assignment. Primary outcome measures 
were changes in abdominal fat areas. Secondary outcomes 
included changes in body weight, waist circumference, total 
and regional body composition, and metabolic risk factors 
such as blood pressure, lipid profiles, and blood glucose 
parameters. Compliance outcomes, ie, dietary intake and 
physical activity, were also measured at baseline and on 
week 12.
anthropometrics
Body weight was measured to the nearest 0.05 kg using 
a calibrated digital scale (WB-150; Tanita, Tokyo, Japan). 
Height was measured to the nearest 0.1 cm using a portable 
stadiometer (213; Seca, Hamburg, Germany) at baseline to 
estimate BMI. BMI was computed as weight in kilograms 
divided by squared height in meters. Waist circumference was 
measured twice to the nearest 0.1 cm at the umbilicus using 
a flexible plastic tape in the standing position. The averaged 
value of the two measurements was used for data analysis. 
abdominal fat areas and body composition
Abdominal fat areas were scanned at the level of the 
umbilicus using computed tomography (ECLOS; Hitachi 
Healthcare Manufacturing, Tokyo, Japan) in the supine 
position and were calculated using a validated commercial 
software program (FatScan; N2system, Osaka, Japan).19 
Total and regional body composition was quantified using 
multifrequency bioelectrical impedance analysis (InBody 
430; Biospace, Seoul, Korea).20 
Blood pressure readings
Systolic and diastolic blood pressure readings were taken 
with an automated sphygmomanometer (HEM-7430; Omron 
Healthcare, Kyoto, Japan) on the arm of seated participants 
who had rested for at least 5 min with the arm supported at 
heart level. The average value of the two readings was used 
for data analysis.
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Blood biochemistry
A blood sample was drawn from each participant after an over-
night (≥12 h) fast. Serum total cholesterol and triglycerides were 
determined enzymatically (Determiner L TG II; Kyowa Medex 
Co., Ltd., Tokyo, Japan). Serum high-density lipoprotein choles-
terol was measured by selective inhibition method (MetaboLead 
HDL-C; Kyowa Medex Co., Ltd.). Serum low-density lipo-
protein cholesterol was estimated according to the Friedewald 
equation (total cholesterol [mg/dL] − high-density lipoprotein 
cholesterol [mg/dL] – triglyceride [mg/dL]/5).21 Blood glucose 
was assayed by hexokinase-G-6-PDH method (L-Type Glu 2; 
Wako Pure Chemical Industries, Ltd., Osaka, Japan), and insu-
lin was measured by electrochemiluminescence immunoassay 
method (ECLusys Insulin; Roche Diagnostics, Tokyo, Japan). 
Glycated hemoglobin A (HbA1c) was determined by latex 
agglutination method (Determiner L HbA1c; Kyowa Medex Co., 
Ltd.). Venous blood was assayed by an independent laboratory 
(Kotobiken Medical Laboratories, Ibaraki, Japan).
Dietary intake
Total energy intake, in kilocalories, and macronutrient intake, 
in grams, were assessed by 3-day weighed food records. Par-
ticipants were asked to record everything they consumed for 
3 days, including 2 weekdays and 1 weekend day. Foods were 
measured using standard measuring cups, spoons, and digital 
scales. To ensure overall comparability, a skilled nutritionist who 
was blinded to the group assignment analyzed all food records. 
Physical activity
Physical activity was measured with a validated triaxial accel-
erometer (Active style Pro HJA-750C; Omron Healthcare) at 
the waist for 14 days. The accelerometer counted daily steps, 
estimated the intensity of physical activity (expressed as meta-
bolic equivalents [METs]), and classified locomotive or non-
locomotive activities with a validated algorithm.22,23 The devices 
were not worn when sleeping, while engaged in a water-based 
activity (eg, bathing or swimming), or while participating in 
activities such as contact sports for safety reasons. Records 
obtained were defined as valid when a device was worn for at 
least 10 h/d.24 When valid records were collected for more than 
3 days, daily step counts, times spent in moderate-to-vigorous 
physical activity (MVPA, ≥3 METs), and locomotive and non-
locomotive MVPA were calculated for each participant.
Sociodemographic and lifestyle variables
Participants also reported sociodemographic and lifestyle 
characteristics via self-administered questionnaires at baseline. 
Characteristics included education (whether a college graduate 
or not), household income (≥ or <5,000,000 yen [equivalent to 
44,000 USD]), current marriage status (married or unmarried), 
and current smoking and drinking habits (yes or no for both). 
adverse events and success of blinding
Adverse events were subjectively reported through participants’ 
diaries and were objectively collected using blood pressure read-
ings and blood hematological and biochemical tests. In this trial, 
an adverse event was defined as any unfavorable and unintended 
sign, symptom, or disease temporarily associated with the inges-
tion of the test beverage, without any judgment about causality. 
The study physician (HK) judged whether a given adverse event 
was serious or non-serious, as well as whether study related or 
not. Participants reported a guess on their own group assignment 
on a post-intervention survey. The response was used to assess 
whether blinding was successful or not.
Statistical analysis
We set the target number of participants at 80 (ie, 20 participants 
in each group). Since this was a pilot trial, there was no statistical 
basis for this sample size setting. However, a sample size of 20 
participants per group allowed us to detect between-group dif-
ference of effect size of 0.9 (Cohen’s d) with a significance level 
of 5% and a detection power of 80%. Assuming that some would 
decline to participate in the trial or not meet eligibility criteria, a 
target number of 100 adults was set for the orientation session.
All statistical analyses were performed in full accordance 
with the analysis plan in the study protocol, using the open-
source statistical environment R (3.2.4 for Windows 64-bit). A 
p-value <0.05 was considered statistically significant. Baseline 
participant characteristics are presented as mean and standard 
deviation for continuous variables or frequency and percentage 
for categorical variables. Our primary analysis was based on an 
intention-to-treat (ITT) principle, with missing data replaced 
by baseline observations carried forward. Primary, secondary, 
and compliance outcomes are presented with mean and 95% 
confidence interval (CI). Next, one-way analysis of variance 
with Dunnett’s post hoc test was employed to examine between-
group differences.
The secondary analysis followed a per-protocol-based (PPB) 
principle, where we excluded those who met at least one of the 
following prespecified criteria: 1) missed the 12-week follow-up 
visit, 2) low compliance rate (<80%) with consumption of the 
test beverages, 3) missing or incomplete diary logs, 4) declared 
ineligible after randomization, and 5) serious violation of study 
compliance judged by the principal investigator (YN) and the 
study physician (HK). Adverse events were also compared 
among the four groups using one-way analysis of variance for 
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continuous variables and chi-squared tests for categorical vari-
ables. To assess the success of blinding, percentages of those 
who correctly identified their group assignment were calculated 
and compared among the four groups using chi-squared tests.
Results
The complete flowchart of the study participants is presented 
in Figure 1. We faced unexpected difficulties in recruiting par-
ticipants and eventually invited 53 candidates to the orientation 
session. Of those invited, 43 adults attended the orientation 
session and gave written informed consent, and 42 completed 
a baseline examination. Of these, 35 met the eligibility criteria 
and were randomly assigned to the high-dose (n=9), medium-
dose (n=9), low-dose (n=8), and placebo groups (n=9). The 35 
randomized participants were subject to the ITT analysis. 
Baseline participant characteristics are presented in Table 1. 
There were no notable differences in sociodemographic and 
lifestyle variables or any other study outcomes between the 
four groups. Of the 35 participants, 32 (91.4%) completed the 
12-week follow-up visit. Two participants dropped out from the 
trial for personal reasons and one was excluded after missing 
the 12-week visit. Among the 32 who completed the trial, the 
median rate of test beverage intake was 95.2% (65.5%–100.0%) 
with no between-group differences (p=0.86). After excluding 
four additional participants (one participant in each group) 
with low compliance of test beverage ingestion (<80%), 28 
participants were included in the PPB analysis. Apart from those 
who missed the 12-week visit, there were five participants with 
missing data for the weighed dietary intake (n=1) and physical 
activity (n=4) at week 12.
Figure 1 Flowchart of study participants.
Abbreviations: BMi, body mass index; iTT, intention to treat; PPB, per protocol based. 
53 invited to
orientation session
43 agreed to
participate
42 screened for
eligibility
35 met eligibility
criteria
Randomized
9 assigned to
high-dose group
(3,000 mg/d)
1 personal
reason
1 intake
rate <80%
1 intake
rate <80%
1 intake
rate <80%
1 intake
rate <80%
1 personal
reason
1 missed 12-
week visit
8 completed 12-
week visit
7 analyzed on
a PPB principle
8 analyzed on
a PPB principle
6 analyzed on
a PPB principle
7 analyzed on
a PPB principle
9 analyzed on
an ITT principle
9 analyzed on
an ITT principle
9 analyzed on
an ITT principle
8 analyzed on
an ITT principle
9 completed 12-
week visit
7 completed 12-
week visit
8 completed 12-
week visit
9 assigned to
medium-dose group
(1,500 mg/d)
8 assigned to
low-dose group
(750 mg/d)
9 assigned to
placebo group
(0 mg/d)
7 excluded
6 BMI <25 kg/m2
1 exercise habit
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The ITT analysis in Table 2 shows that the changes in 
abdominal total fat area were −14.6 cm2, −25.3 cm2, −23.2 cm2, 
and −12.5 cm2 in the high-dose, medium-dose, low-dose, and 
placebo groups, respectively. Changes in abdominal visceral fat 
area were −5.4 cm2, −12.0 cm2, −13.5 cm2, and −4.7 cm2 in the 
high-dose, medium-dose, low-dose, and placebo groups, respec-
tively. Similar results were obtained for the change in  abdominal 
subcutaneous fat area. Although significant differences in 
diastolic blood pressure and HbA1c were observed in the four 
groups, Dunnett’s post hoc test detected no significant differ-
ences from the placebo group. No significant between-group 
differences were found for any of the primary and secondary 
outcomes. As for the compliance outcome measures, daily total 
energy intake increased slightly by 18.4 kcal in the high-dose 
Table 1 Baseline participant characteristics
High-dose group 
(3,000 mg/d, n=9)
Medium-dose group 
(1,500 mg/d, n=9)
Low-dose group 
(750 mg/d, n=8)
Placebo group 
(0 mg/d, n=9)
Female, no. (%) 4 (44.4) 5 (55.6) 4 (50.0) 4 (44.4)
age, years 44.3 (9.4) 39.7 (8.0) 41.9 (10.5) 46.4 (9.4)
college/university graduates, no. (%) 6 (66.7) 5 (55.6) 5 (62.5) 4 (44.4)
household income ($50,000+), no. (%) 5 (55.6) 4 (44.4) 6 (75.0) 5 (55.6)
Married, no. (%) 6 (66.7) 6 (66.7) 5 (62.5) 7 (77.8)
current cigarette smoking, no. (%) 2 (22.2) 0 (0.0) 1 (12.5) 1 (11.1)
current alcohol drinking, no. (%) 6 (66.7) 8 (88.9) 4 (50.0) 4 (44.4)
height, cm 165.9 (7.8) 166.8 (10.5) 164.6 (11.0) 161.9 (9.4)
Weight, kg 75.8 (9.6) 76.4 (13.4) 72.5 (12.1) 71.0 (9.1)
Body mass index, kg/m2 27.4 (1.3) 27.2 (1.6) 26.6 (1.4) 27.0 (1.0)
Waist circumference, cm 93.8 (4.0) 95.3 (7.7) 93.4 (8.8) 95.0 (5.8)
abdominal fat area, cm2
Total 300.1 (45.6) 340.0 (68.9) 326.3 (114.8) 357.2 (71.7)
Subcutaneous 197.8 (37.8) 232.5 (39.5) 196.1 (38.2) 231.4 (70.7)
Visceral 102.3 (44.0) 107.5 (50.0) 130.2 (99.6) 125.8 (32.6)
Fat mass, kg 22.8 (4.4) 23.8 (3.7) 22.8 (4.0) 24.5 (4.2)
Fat-free mass, kg 49.9 (10.1) 49.6 (10.6) 47.0 (8.9) 44.0 (7.6)
Fat mass, %
Total 30.6 (7.0) 31.5 (4.1) 31.6 (3.7) 34.6 (5.3)
right arm 33.9 (11.2) 35.5 (5.6) 34.6 (5.6) 38.4 (7.2)
left arm 34.2 (11.7) 35.6 (5.4) 35.8 (5.7) 39.0 (7.1)
Trunk 32.4 (6.3) 33.4 (3.4) 33.3 (3.2) 35.8 (4.5)
right leg 28.5 (7.0) 29.1 (4.2) 29.5 (4.3) 32.2 (5.5)
left leg 28.5 (7.1) 29.1 (4.3) 29.2 (4.1) 32.3 (5.3)
Blood pressure, mmhg
Systolic 134.3 (16.8) 138.9 (22.4) 130.5 (14.7) 127.3 (15.0)
Diastolic 85.0 (9.9) 86.6 (11.5) 82.4 (12.5) 82.1 (9.1)
Blood biochemical parameters
Triglycerides, mg/dl 130.0 (66.4) 146.7 (107.1) 133.4 (106.8) 150.7 (97.6)
Total cholesterol, mg/dl 210.7 (36.9) 218.7 (35.8) 192.8 (20.9) 253.6 (55.7)
hDl cholesterol, mg/dl 57.0 (20.9) 56.2 (9.6) 54.4 (20.6) 49.0 (11.1)
lDl cholesterol, mg/dl 132.9 (30.5) 137.9 (38.1) 116.4 (17.6) 176.1 (47.3)
Fasting blood glucose, mg/dl 91.6 (7.2) 91.8 (7.5) 94.5 (13.6) 97.2 (10.9)
glycated hemoglobin a1c, % 5.43 (0.23) 5.29 (0.29) 5.62 (0.89) 5.56 (0.35)
Fasting insulin, iU 9.1 (3.1) 17.2 (14.9) 9.6 (4.0) 17.3 (21.7)
Dietary intake
Total energy, kcal/d 2,361 (539) 1,998 (383) 2,216 (420) 2,212 (938)
Protein, g/d 83.9 (14.3) 69.6 (9.8) 86.5 (25.4) 79.7 (30.0)
Fat, g/d 85.9 (28.5) 66.6 (15.9) 73.0 (10.5) 85.3 (59.8)
carbohydrate, g/d 295.9 (57.6) 268.7 (71.6) 282.1 (58.6) 266.8 (92.9)
Physical activity
Daily step counts, steps/d 5,611 (3,484) 6,974 (2,882) 6,172 (2,786) 6,327 (3,121)
MVPa, min/d 53.7 (32.5) 67.6 (36.4) 49.3 (17.2) 59.1 (33.6)
locomotive MVPa, min/d 26.7 (22.5) 34.4 (29.4) 30.6 (16.0) 29.1 (23.9)
non-locomotive MVPa, min/d 26.9 (26.2) 33.2 (35.1) 18.7 (9.3) 29.9 (25.5)
Notes: Data shown as mean (standard deviation) unless specified.
Abbreviation: hDl, high-density lipoprotein; lDl, low-density lipoprotein; MVPa, moderate-to-vigorous physical activity.
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group and 25.0 kcal in the medium-dose group, and decreased by 
171.5 kcal in the low-dose group and 372.0 kcal in the placebo 
group. Daily step counts increased by 1,854, 196, 2,518, and 
284, in the high-dose, medium-dose, low-dose, and the placebo 
groups, respectively. There were no significant differences in 
any of the study compliance outcomes among the four groups. 
The PPB analysis (n=28) also demonstrated no between-group 
differences in any of the study outcomes (Table S1).
No serious adverse events were reported throughout the trial. 
A total of 34 non-serious adverse events were reported through 
participants’ diaries (Table S2). These events included fever, 
headache, toothache, bodily pains, and common gastroentero-
logical symptoms such as diarrhea and constipation. Similarly, 
29 abnormal signs (ie, out of the reference range) were newly 
identified through blood pressure readings and fasting blood tests 
conducted at week 12 (Table S3). There were no  between-group 
Table 2 intention-to-treat analyses for primary, secondary, and compliance outcomes (n=35)
High-dose group 
(3,000 mg/d,  
n=9)
Medium-dose 
group (1,500 
mg/d, n=9)
Low-dose group 
(750 mg/d, n=8)
Placebo group 
(0 mg/d, n=9)
p-value  
for  
ANOVA
Primary outcomes
abdominal fat area, cm2
Total
−14.6 (−39.6, 10.4) −25.3 (−71.0, 20.3) −23.2 (−48.0, 1.6) −12.5 (−29.1, 4.0) 0.87
Subcutaneous
−9.3 (−23.3, 4.8) −13.3 (−47.2, 20.6) −9.7 (−25.3, 5.9) −7.9 (−20.2, 4.5) 0.98
Visceral
−5.4 (−20.6, 9.8) −12.0 (−26.0, 2.0) −13.5 (−32.1, 5.1) −4.7 (−14.6, 5.2) 0.67
Secondary outcomes
Weight, kg
−0.87 (−2.23, 0.49) −1.32 (−5.20, 2.56) −1.04 (−2.63, 0.56) −0.33 (−1.57, 0.91) 0.91
Waist circumference, cm
−1.58 (−3.10, −0.05) −0.70 (−4.55, 3.15) −1.39 (−2.96, 0.18) −0.23 (−1.98, 1.52) 0.78
Fat mass, kg
−0.29 (−1.58, 1.00) −1.36 (−3.35, 0.64) −1.53 (−3.13, 0.08) −0.63 (−1.84, 0.57) 0.53
Fat-free mass, kg
−0.46 (−1.50, 0.59) 0.10 (−1.87, 2.07) 0.41 (−0.56, 1.38) 0.22 (−0.31, 0.75) 0.71
Fat mass, %
Total
−0.03 (−1.42, 1.36) −1.31 (−2.83, 0.21) −1.71 (−3.69, 0.27) −0.60 (−1.67, 0.47) 0.28
right arm
−0.03 (−2.20, 2.13) −1.96 (−3.67, −0.24) −2.50 (−4.97, −0.03) −1.06 (−2.24, 0.13) 0.19
left arm 0.28 (−2.09, 2.65) −1.62 (−3.11, −0.13) −2.70 (−5.23, −0.17) −0.97 (−2.22, 0.29) 0.11
Trunk
−0.12 (−1.57, 1.33) −1.37 (−2.89, 0.16) −1.74 (−3.79, 0.31) −0.57 (−1.50, 0.37) 0.30
right leg
−0.03 (−1.24, 1.18) −0.99 (−2.27, 0.29) −1.54 (−3.22, 0.14) −0.58 (−1.54, 0.38) 0.29
left leg
−0.07 (−1.32, 1.18) −1.04 (−2.26, 0.17) −1.48 (−3.12, 0.17) −0.67 (−1.65, 0.31) 0.34
Blood pressure, mmhg
Systolic
−6.17 (−10.12, −2.21) 3.94 (−3.24, 11.13) −3.56 (−9.06, 1.93) −1.89 (−8.53, 4.76) 0.06
Diastolic
−7.67 (−12.71, −2.63) 0.17 (−3.65, 3.98) −3.31 (−6.49, −0.14) −2.44 (−6.74, 1.85) 0.03
Blood biochemical parameters
Triglycerides, mg/dl
−23.6 (−69.6, 22.5) 6.6 (−76.8, 89.9) −24.9 (−70.6, 20.8) −2.9 (−33.9, 28.1) 0.74
Total cholesterol, mg/dl
−17.0 (−35.1, 1.1) −14.9 (−29.0, −0.7) −11.6 (−27.8, 4.6) −10.6 (−20.9, −0.2) 0.89
hDl cholesterol, mg/dl
−6.33 (−14.91, 2.24) −4.00 (−9.24, 1.24) 1.50 (−4.85, 7.85) −1.11 (−4.15, 1.93) 0.20
lDl cholesterol, mg/dl
−11.8 (−27.5, 4.0) −14.0 (−28.3, 0.3) −12.0 (−27.2, 3.2) −9.4 (−16.5, −2.4) 0.96
Fasting blood glucose, mg/dl 0.00 (−5.64, 5.64) 0.67 (−2.75, 4.08) 2.38 (−11.35, 16.10) 0.33 (−3.82, 4.49) 0.96
glycated hemoglobin a1c, %
−0.02 (−0.12, 0.08) 0.00 (−0.07, 0.07) 0.14 (0.01, 0.26) 0.09 (−0.01, 0.19) 0.04
Fasting insulin, iU 0.37 (−1.86, 2.59) −5.54 (−15.23, 4.14) −0.61 (−4.49, 3.26) 0.43 (−2.43, 3.30) 0.26
Compliance measures
Dietary intake
Total energy, kcal/d 18.4 (−389.7, 426.6) 25.0 (−510.1, 560.1) −171.5 (−442.1, 99.1) −372.0 (−846.1, 102.1) 0.41
Protein, g/d 1.4 (−10.9, 13.7) 3.0 (−17.1, 23.1) −12.0 (−27.4, 3.4) −11.9 (−21.2, −2.6) 0.20
Fat, g/d
−3.1 (−20.7, 14.5) −0.9 (−19.3, 17.5) 2.3 (−11.7, 16.2) −25.7 (−70.0, 18.7) 0.33
carbohydrate, g/d 13.8 (−61.7, 89.2) −4.3 (−70.7, 62.0) −39.1 (−79.0, 0.9) −17.9 (−44.7, 8.9) 0.50
Physical activity
Daily step counts, steps/d 1,854 (−1,538, 5,246) 196 (−1,749, 2,142) 2,518 (−670, 5,706) 284 (−152, 720) 0.35
MVPa, min/d 12.6 (−17.1, 42.2) −4.9 (−21.8, 12.1) 22.5 (−4.5, 49.5) 2.6 (−6.8, 11.9) 0.22
locomotive MVPa, min/d 13.8 (−15.1, 42.6) −1.0 (−13.7, 11.6) 18.6 (−5.0, 42.2) 5.0 (−3.8, 13.7) 0.40
non-locomotive MVPa, min/d
−1.22 (−9.23, 6.79) −3.83 (−12.99, 5.32) 3.92 (−1.96, 9.79) −2.43 (−6.41, 1.54) 0.35
Notes: Data shown as mean (95% confidence intervals).
Abbreviations: anOVa, analysis of variance; hDl, high-density lipoprotein; lDl, low-density lipoprotein; MVPa, moderate-to-vigorous physical activity.
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differences in any of the identified adverse events, none of 
which were judged study related by the study physician (HK). 
Among those who completed the 12-week visit (n=32), the 
numbers (percentage) of participants who correctly identified 
their own group assignment were 0 (0%), 2 (22.2%), 2 (28.6%), 
and 2 (25.0%) in the high-dose, medium-dose, low-dose, and 
placebo groups, respectively. No between-group differences 
were found (p=0.46).
Discussion
The objective of the study was to determine an effective dose of 
A-mix combined with physical activity promotion in reducing 
abdominal fat among overweight adults. We found a trend for 
larger reductions in abdominal fat area in the medium-dose and 
low-dose groups, compared with the placebo group. This finding 
could be applicable to other body composition outcomes. From 
a safety perspective, no serious or study-related adverse events 
were identified throughout the study. Although common gas-
troenterological symptoms and some abnormal ranges of blood 
biochemistry were identified, these adverse events occurred 
independent of group assignment (ie, A-mix doses).
The relatively large reduction in abdominal fat in the 
medium-dose and low-dose groups could be explained by the 
following physiological mechanisms. A previous study14 dem-
onstrated that pre-exercise ingestion of A-mix increased blood 
concentrations of adrenaline and glucagon during and post-
exercise. Aerobic exercise leads to a fall in serum insulin and a 
rise in glucagon concentrations, which protect against a severe 
decline in blood glucose levels. Gannon and Nuttall reported 
that specific amino acids such as arginine can stimulate glucagon 
secretion.25 Therefore, reduction in blood glucose by exercise 
and a transient increase in blood amino acid levels by ingestion 
may stimulate pancreatic alpha cells and promote glucagon 
secretion. Furthermore, previous reports have noted that several 
widely divergent effects of adrenaline and glucagon appear 
to be mediated by a common effector, adenosine 3′,5′-cyclic 
monophosphate (cAMP).26 The best-known mechanism mediat-
ing lipolysis is the cAMP pathway, wherein increased levels of 
cAMP activate cAMP-dependent protein kinase A (PKA). In 
this pathway, hormone-sensitive lipase (HSL) is phosphorylated 
by PKA and then translocates from the cytoplasm to the lipid 
droplet surface, where it interacts with perilipin A, the result of 
which is a subsequent release of free fatty acids.27,28 HSL is the 
most important lipase in lipolysis and is subject to hormonal 
regulation.29 In addition to HSL, adipose triglyceride lipase is 
expressed predominantly in adipose tissue and is considered 
the rate-limiting lipolytic enzyme in adipocytes.30,31 Therefore, 
an additional effect by A-mix supplementation combined with 
physical activity may stimulate the cAMP-dependent cascade 
pathway. Previous in vitro studies in human cells found that 
lipolytic responses to adrenalin in visceral adipocytes are 1.5–3.0 
times higher than the responses in subcutaneous adipocytes.32,33 
Therefore, abdominal fat tissues are one target of the exercise-
induced lipolysis. c-AMP-dependent lipolysis may, therefore, 
increase following acute administration of A-mix combined 
with exercise, and the accumulated effects may have reduced 
abdominal fat in the current study.
The reasons for the relative ineffectiveness of the high dose 
remain unknown. One possible explanation may be an insuf-
ficiently robust point estimate of the primary outcomes due 
to small sample size. The placebo and the high-dose groups 
showed similar reductions in abdominal fat areas. This may be 
explained by greater reduction in energy intake (−372 kcal/d) 
in the placebo group.
Of the secondary outcomes, changes in diastolic blood pres-
sure and HbA1c significantly differed among the four groups 
(Table 2). However, neither dose–response relationships nor 
significant differences from the placebo group were found 
for the two outcomes. In a future large-scale trial, we should 
assess whether A-mix ingestion combined with physical activity 
improves blood pressure and glycemic control.
Compliance measures in dietary intake and physical activity 
differed among the four groups. Energy intake increased slightly 
in the high-dose and medium-dose groups, but decreased in the 
low-dose and placebo groups. The increases in step counts were 
greater in the high-dose and low-dose groups. Participants in 
the low-dose group showed reduced energy intake and increased 
step counts, suggesting substantial energy deficits compared 
with the other three groups. Therefore, a dose of 1,500 mg/d, 
which was used in the medium-dose group, may be a reasonable 
choice for a future larger trial.
In this trial, no serious or study-related adverse events 
occurred and no dose-dependent relationship was identified. 
Most of the adverse events were common gastroenterological 
and neurological symptoms, along with bodily pain. These 
symptoms frequently occurred following beverage intake in 
general and exercise, especially for previously inactive individu-
als. Therefore, the A-mix doses used in this trial are less likely to 
create serious safety concerns over long-term ingestion.
Our study has several noteworthy strengths. 1) This trial 
adopted the research design of a placebo-controlled, double-
blind, parallel-group, randomized trial. The post-intervention 
survey showed the success of blinding to participants, suggesting 
a low risk of bias in this trial. Therefore, the findings are highly 
reliable. 2) Abdominal fat areas, as primary outcomes, were 
assessed by computed tomography, which is regarded as a gold 
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standard in evaluating abdominal fat. 3) The study provided a 
physical activity promotion intervention designed to encourage 
participants to add ~1,000 daily steps. This type of mild interven-
tion, rather than a strictly supervised exercise program, can be 
easily adopted by the general population.17,18 4) The study had 
a high retention rate of 91%.
In contrast, we must also note some limitations. 1) The 
number of enrolled participants was 35, much lower than the 
target number of 80. Therefore, the data robustness may not be 
high. 2) Despite careful instructions on dietary habits and other 
lifestyle factors, changes in compliance outcomes such as total 
and macronutrient intake and daily physical activity differed 
in the four study groups. These between-group differences in 
compliance outcomes were not significant, but they may have 
affected the study results.
Conclusion
A low or medium dose of the amino acid mixture may facilitate 
abdominal fat reduction among overweight adults. A larger 
randomized trial using A-mix doses of 750 or 1,500 mg/d with 
sufficient statistical power should be implemented to validate 
the effectiveness of this supplement.
Acknowledgments
This trial was based on a collaborative research agreement 
between the University of Tsukuba Faculty of Medicine and 
Meiji Co., Ltd. We acknowledge Mr Takuya Nagai who pro-
duced and provided the test beverages used in this trial, Mr Akio 
Tanaka who was in charge of shipping the test beverages to the 
study participants, Dr Keiko Fujie who generated randomiza-
tion codes and created an allocation table, Dr Koichi Hashi-
moto who was in charge of managing participants’ personal 
identification information, and Ms Yuriko Sakairi who provided 
administrative support and her technical expertise in the data 
collection. We also gratefully acknowledge the contribution 
of all the trial staff.
Author contributions
Study concept and design: KU, CS, SI, and YN; intervention: 
HS, TT, and YN; data acquisition: all authors; statistical analysis: 
HS and YN; interpretation: HS and YN; writing the first draft: 
HS and KU; significant revision: all authors; study physician: 
HK; overall supervision as a principal investigator: YN.
Disclosure
KU, CS, and SI are employees of Meiji Co., Ltd. The authors 
report no other conflicts of interest in this work. 
References
1. Nishi N. Monitoring obesity trends in Health Japan 21. J Nutr Sci Vitaminol 
(Tokyo). 2015;61(Suppl):S17–S19.
2. Ministry of Health, Labour and Welfare. Report on National Health and 
Nutrition Survey 2015. Available from: http://www.mhlw.go.jp/bunya/
kenkou/eiyou/dl/h27-houkoku.pdf. Accessed March 27, 2017.
3. Ministry of Health, Labour and Welfare. Report on National Health and 
Nutrition Survey 2006. Available from: http://www.mhlw.go.jp/hou-
dou/2008/04/dl/h0430-2c.pdf. Accessed March 27, 2017.
4. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/
American Heart Association Task Force on Practice Guidelines; Obesity 
Society. 2013 AHA/ACC/TOS guideline for the management of overweight 
and obesity in adults: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines and the 
Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–S138.
5. Kim HK, Suzuki T, Saito K, Yoshida H, Kobayashi H, Kato H, Katayama 
M. Effects of exercise and amino acid supplementation on body com-
position and physical function in community-dwelling elderly Japanese 
sarcopenic women: a randomized controlled trial. J Am Geriatr Soc. 2012; 
60(1):16–23.
6. Michishita T, Kobayashi S, Katsuya T, Ogihara T, Kawabuchi K. Evaluation 
of the antiobesity effects of an amino acid mixture and conjugated linoleic 
acid on exercising healthy overweight humans: a randomized, double-blind, 
placebo-controlled trial. J Int Med Res. 2010;38(3):844–859.
7. Abe T, Takiguchi Y, Tamura M, Shimura J, Yamazaki K-I. Effect of vespa 
amino acid mixture (VAAM) isolated from hornet larval saliva and modified 
VAAM nutrients on endurance exercise in swimming mice – improvement 
in performance and changes of blood lactate and glucose. Jpn J Phys Fitness 
Sports Med. 1995;44(2):225–238.
8. Abe T, Inamori M, Iida K, Tamura M, Takiguchi Y, Yasuda K. The activa-
tion of fatty acid metabolism by vespa amino acid mixture (VAAM) and 
related nutrients during endurance exercise in mice. Adv Exerc Sports 
Physiol. 1997;3(1):35–44.
9. Tsuchita H, Shirai-Morishita Y, Shimizu T, Abe T. Effects of a vespa amino 
acid mixture identical to hornet larval saliva on the blood biochemical 
indices of running rats. Nutr Res. 1997;17(6):999–1012.
10. Mizuno K, Asano K, Abe T, Morishita K. [Effects of ingestion of hornet 
larval salivary amino acid mixture (HLSA) on metabolic responses during 
exercise]. Sci Fatigue Rest. 1997;12(1):31–41. Japanese.
11. Saito S, Tsuchita H, Mukai N, Abe T. [Effects of ingestion of vespa amino 
acid mixture (VAAM) under postprandial conditions on blood ketone body 
concentrations during prolonged exercise in humans]. Bull Inst Health Sport 
Sci Univ Tsukuba. 2001;24:71–78. Japanese.
12. Sasai H, Matsuo T, Fujita M, Saito M, Tanaka K. Effects of regular exercise 
combined with ingestion of vespa amino acid mixture on aerobic fitness and 
cardiovascular disease risk factors in sedentary older women: a preliminary 
study. Geriatr Gerontol Int. 2011;11(1):24–31.
13. Ueda K, Nakamura Y, Yamaguchi M, Mori T, Uchida M, Fujita S. 
Amino acid mixture enriched with arginine, alanine, and phenylalanine 
stimulates fat metabolism during exercise. Int J Sport Nutr Exerc Metab. 
2016;26(1):46–54.
14. Ueda K, Sanbongi C, Takai S, Ikegami S, Fujita S. Combination of aerobic 
exercise and an arginine, alanine, and phenylalanine mixture increases 
fat mobilization and ketone body synthesis. Biosci Biotechnol Biochem. 
2017;81(7):1417–1424.
15. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 
statement: updated guidelines for reporting parallel group randomized 
trials. Ann Intern Med. 2010;152(11):726–732.
16. Miyachi M, Tripette J, Kawakami R, Murakami H. “+10 min of physical 
activity per day”: Japan is looking for efficient but feasible recommendations 
for its population. J Nutr Sci Vitaminol (Tokyo). 2015;61(Suppl):S7–S9.
17. Murakami H, Tripette J, Kawakami R, Miyachi M. “Add 10 min for 
your health”: the new Japanese recommendation for physical activ-
ity based on dose-response analysis. J Am Coll Cardiol. 2015;65(11): 
1153–1154.
 
D
ia
be
te
s,
 M
et
ab
ol
ic 
Sy
nd
ro
m
e 
an
d 
O
be
sit
y:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
8.
56
.9
2 
on
 0
8-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
306
Sasai et al
18. Kurotani K, Akter S, Kashino I, et al; Japan Public Health Center based 
Prospective Study Group. Quality of diet and mortality among Japanese 
men and women: Japan Public Health Center based prospective study. 
BMJ. 2016;352:i1209.
19. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized 
technique for measurement at CT. Radiology 1999;211(1):283–286.
20. Shafer KJ, Siders WA, Johnson LK, Lukaski HC. Validity of segmental 
multiple-frequency bioelectrical impedance analysis to estimate body 
composition of adults across a range of body mass indexes. Nutrition 
2009;25(1):25–32.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentra-
tion of low-density lipoprotein cholesterol in plasma, without use of the 
preparative ultracentrifuge. Clin Chem 1972;18(6):499–502.
22. Oshima Y, Kawaguchi K, Tanaka S, et al. Classifying household and 
locomotive activities using a triaxial accelerometer. Gait Posture. 
2010;31(3):370–374.
23. Ohkawara K, Oshima Y, Hikihara Y, Ishikawa-Takata K, Tabata I, Tanaka 
S. Real-time estimation of daily physical activity intensity by a triaxial 
accelerometer and a gravity-removal classification algorithm. Br J Nutr. 
2011;105(11):1681–1691.
24. Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, McDowell M. 
Physical activity in the United States measured by accelerometer. Med Sci 
Sports Exerc. 2008;40(1):181–188.
25. Gannon MC, Nuttall FQ. Amino acid ingestion and glucose metabolism – a 
review. IUBMB Life. 2010;62(9):660–668.
26. Blecher M, Merlino NS, Ro’Ane JT, Flynn PD. Independence of the 
effects of epinephrine, glucagon, and adrenocorticotropin on glucose uti-
lization from those on lipolysis in isolated rat adipose cells. J Biol Chem. 
1969;244(13):3423–3429.
27. Holm C. Molecular mechanisms regulating hormone-sensitive lipase and 
lipolysis. Biochem Soc Trans. 2003;31(Pt 6):1120–1124.
28. Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell 
Signal. 2006;18(4):401–408.
29. Rayalam S, Della-Fera MA, Baile CA. Phytochemicals and regulation of 
the adipocyte life cycle. J Nutr Biochem. 2008;19(11):717–726.
30. Haemmerle G, Lass A, Zimmermann R, et al. Defective lipolysis and altered 
energy metabolism in mice lacking adipose triglyceride lipase. Science. 
2006;312(5774):734–737.
31. Zechner R, Strauss JG, Haemmerle G, Lass A, Zimmermann R. Lipolysis: 
pathway under construction. Curr Opin Lipidol. 2005;16(3):333–340.
32. Robuffe-Scrive M, Anderson B, OIbe L, Bjorntorp. Metabolism of adi-
pose tissue in intraabdominal depots in severely obese men and women. 
Metabolism. 1990;39(10):1021–1025.
33. Richeisen B, Pedersen SB, Moller-Pedersen T, Bak JF. Regional differences 
in triglyceride breakdown in human adipose tissue: effects of catechol-
amines, insulin, and prostaglandin E2. Metabolism. 1991;40(9):990–996.
 
D
ia
be
te
s,
 M
et
ab
ol
ic 
Sy
nd
ro
m
e 
an
d 
O
be
sit
y:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
8.
56
.9
2 
on
 0
8-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
307
amino acid mixture with physical activity and abdominal fat
Supplementary materials 
Table S1 Per-protocol-based analyses for primary, secondary, and compliance outcomes (n=28)
High-dose group 
(3,000 mg/d, n=7)
Medium-dose  
group (1,500  
mg/d, n=8)
Low-dose group 
(750 mg/d, n=6)
Placebo group 
(0 mg/d, n=7)
p-value  
for  
ANOVA
Primary outcomes
abdominal fat area, cm2
Total
−17.4 (−51.6, 16.7) −21.4 (−73.4, 30.7) −27.9 (−62.6, 6.8) −16.1 (−37.8, 5.6) 0.96
Subcutaneous
−11.2 (−30.2, 7.8) −8.1 (−45.0, 28.7) −11.5 (−34.1, 11.1) −9.5 (−26.3, 7.2) 1.00
Visceral
−6.2 (−27.2, 14.8) −13.2 (−29.2, 2.7) −16.4 (−43.0, 10.3) −6.6 (−19.7, 6.6) 0.75
Secondary outcomes
Weight, kg
−1.32 (−2.91, 0.27) −1.40 (−5.91, 3.11) −1.33 (−3.60, 0.95) −0.25 (−1.93, 1.43) 0.90
Waist circumference, cm
−2.02 (−3.92, −0.12) −0.70 (−5.17, 3.77) −1.97 (−3.88, −0.06) 0.09 (−2.14, 2.32) 0.61
Fat mass, kg
−0.44 (−2.20, 1.31) −1.33 (−3.64, 0.99) −2.13 (−4.05, −0.22) −0.64 (−2.29, 1.00) 0.50
Fat-free mass, kg
−0.71 (−2.03, 0.60) 0.00 (−2.28, 2.28) 0.63 (−0.70, 1.97) 0.39 (−0.24, 1.01) 0.54
Fat mass, %
Total
−0.06 (−1.99, 1.87) −1.28 (−3.04, 0.49) −2.43 (−4.85, −0.02) −0.66 (−2.12, 0.80) 0.21
right arm 0.07 (−2.92, 3.07) −1.87 (−3.86, 0.11) −3.62 (−6.18, −1.06) −1.03 (−2.55, 0.49) 0.08
left arm 0.50 (−2.74, 3.74) −1.53 (−3.24, 0.19) −3.65 (−6.70, −0.60) −1.09 (−2.79, 0.62) 0.07
Trunk
−0.17 (−2.18, 1.84) −1.34 (−3.11, 0.43) −2.48 (−4.98, 0.01) −0.61 (−1.90, 0.67) 0.22
right leg
−0.01 (−1.69, 1.66) −0.92 (−2.40, 0.55) −2.18 (−4.17, −0.20) −0.70 (−2.01, 0.61) 0.18
left leg
−0.03 (−1.76, 1.70) −0.99 (−2.39, 0.41) −2.12 (−4.04, −0.19) −0.80 (−2.13, 0.53) 0.21
Blood pressure, mmhg
Systolic
−6.43 (−11.12, −1.74) 3.50 (−4.77, 11.77) −3.58 (−11.40, 4.24) −2.50 (−11.64, 6.64) 0.16
Diastolic
−9.14 (−15.26, −3.02) −0.69 (−4.49, 3.11) −3.42 (−7.68, 0.85) −3.14 (−8.93, 2.64) 0.05
Blood biochemical parameters
Triglycerides, mg/dl
−19.3 (−79.2, 40.7) −25.5 (−70.2, 19.2) −32.7 (−98.1, 32.8) −2.9 (−45.9, 40.2) 0.80
Total cholesterol, mg/dl
−19.6 (−43.8, 4.6) −13.2 (−29.1, 2.6) −18.5 (−35.7, −1.3) −11.1 (−24.7, 2.5) 0.83
hDl cholesterol, mg/dl
−6.57 (−18.11, 4.97) −4.12 (−10.21, 1.96) 1.00 (−8.15, 10.15) −1.29 (−5.48, 2.91) 0.43
lDl cholesterol, mg/dl
−14.7 (−35.7, 6.3) −9.2 (−19.9, 1.4) −17.8 (−35.7, −0.0) −10.6 (−19.6, −1.5) 0.75
Fasting blood glucose, mg/dl
−0.14 (−7.96, 7.68) 0.88 (−3.06, 4.81) 3.17 (−17.13, 23.47) 1.14 (−4.21, 6.49) 0.95
glycated hemoglobin a1c, %
−0.03 (−0.17, 0.11) −0.01 (−0.08, 0.06) 0.15 (−0.02, 0.32) 0.11 (−0.01, 0.24) 0.05
Fasting insulin, iU 0.77 (−2.15, 3.69) −5.71 (−16.96, 5.54) −2.30 (−5.36, 0.76) 0.56 (−3.42, 4.53) 0.36
Compliance measures
Dietary intake
Total energy, kcal/d 4.1 (−561.0, 569.2) −133.4 (−588.1, 321.3) −123.5 (−448.3, 201.3) −211.4 (−474.7, 51.8) 0.86
Protein, g/d 3.3 (−13.2, 19.7) −4.4 (−16.6, 7.8) −10.9 (−31.4, 9.5) −9.9 (−16.9, −3.0) 0.32
Fat, g/d
−8.61 (−28.27, 11.04) −5.12 (−23.26, 13.01) 5.57 (−12.97, 24.10) −8.06 (−23.12, 7.00) 0.55
carbohydrate, g/d 21.8 (−81.4, 124.9) −16.1 (−86.5, 54.3) −38.3 (−90.9, 14.3) −20.9 (−57.4, 15.6) 0.56
Physical activity
Daily step counts, steps/d 2,594 (−1,833, 7,021) 20 (−2,192, 2,232) 3,651 (−261, 7,562) 365 (−216, 945) 0.15
MVPa, min/d 17.2 (−22.9, 57.2) −7.5 (−25.9, 10.9) 31.9 (−1.7, 65.5) 3.3 (−9.6, 16.1) 0.10
locomotive MVPa, min/d 19.1 (−19.3, 57.5) −1.8 (−16.3, 12.8) 26.8 (−2.6, 56.2) 6.4 (−5.4, 18.2) 0.22
non-locomotive MVPa, min/d
−1.95 (−12.95, 9.05) −5.71 (−15.09, 3.66) 5.08 (−3.22, 13.38) −3.13 (−8.45, 2.19) 0.24
Notes: Data shown as mean (95% confidence intervals).
Abbreviations: anOVa, analysis of variance; hDl, high-density lipoprotein; lDl, low-density lipoprotein; MVPa, moderate-to-vigorous physical activity.
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Table S2 Adverse events identified by participant’s diary logs (n=35)
High-dose group 
(3,000 mg/d, n=9)
Medium-dose group 
(1,500 mg/d, n=9)
Low-dose group 
(750 mg/d, n=8)
Placebo group 
(0 mg/d, n=9)
p-value for  
chi-squared test
asthma 0 0 0 1 (11) 0.40
Tongue numbness 0 0 1 (13) 0 0.32
Diarrhea 0 1 (11) 1 (13) 2 (22) 0.53
constipation 0 0 0 1 (11) 0.40
gastroenteritis 0 1 (11) 0 0 0.40
Fever 2 (22) 1 (11) 2 (25) 0 0.43
Influenza 0 0 1 (13) 0 0.32
headache 1 (11) 0 0 1 (11) 0.57
Toothache 0 0 0 1 (11) 0.40
excessive sweating 1 (11) 0 0 0 0.40
Frequent urination 0 0 1 (13) 0 0.32
Fatigue 1 (11) 0 1 (13) 0 0.52
Foot pain 1 (11) 1 (11) 1 (13) 0 0.77
Knee pain 2 (22) 0 0 0 0.11
calf pain 0 0 0 1 (11) 0.40
leg lameness 1 (11) 0 0 0 0.40
leg cramp 1 (11) 0 0 0 0.40
Shin pain 1 (11) 0 0 0 0.40
Muscle pain 1 (11) 0 0 0 0.40
Back pain 0 1 (11) 0 0 0.40
Scapular pain 1 (11) 0 0 0 0.40
Wrist pain 0 0 1 (13) 0 0.32
Notes: Data shown as no. (%).
Table S3 Adverse events identified during the study period by blood pressure recordings and fasting blood test (n=35)
Reference ranges High-dose  
group (3,000 
mg/d, n=9)
Medium-dose  
group (1,500  
mg/d, n=9)
Low-dose  
group (750 
mg/d, n=8)
Placebo  
group  
(0 mg/d, n=9)
p-value for  
chi-squared  
test
elevated diastolic BP <90 mmhg 0 0 1 (13) 0 0.32
Decreased total protein 6.5–8.2 g/dl 0 0 2 (25) 0 0.07
Decreased aST 11–35 U/l 1 (11) 0 0 0 0.40
elevated ggT ≤70 U/l (male)  
≤33 U/l (female)
0 1 (11) 0 0 0.40
elevated cPK 62–287 U/l (male)  
45–163 U/l (female)
0 0 0 1 (11) 0.40
Decreased cPK 62–287 U/l (male)  
45–163 U/l (female)
0 0 1 (13) 0 0.32
Decreased total cholesterol 130–219 mg/dl 1 (11) 0 0 0 0.40
Decreased hDl cholesterol 40–79 mg/dl (male)  
40–90 mg/dl (female)
1 (11) 0 0 0 0.40
elevated lDl cholesterol 70–139 mg/dl 1 (11) 1 (11) 0 0 0.57
elevated triglycerides 30–149 mg/dl 1 (11) 0 0 1 (11) 0.57
Decreased urea nitrogen 8.0–23.0 mg/dl 0 1 (11) 1 (13) 0 0.52
elevated serum potassium 2.5–4.5 mg/dl 1 (11) 0 0 0 0.40
elevated serum iron 60–190 μg/dl (male)  
45–170 μg/dl (female)
0 0 0 1 (11) 0.40
Decreased serum iron 60–190 μg/dl (male)  
45–170 μg/dl (female)
0 1 (11) 0 1 (11) 0.57
elevated a/g 1.10–2.00 0 0 1 (13) 0 0.32
elevated WBc 3,900–9,700 count/μl (male)  
3,500–9,100 count/μl (female)
0 0 1 (13) 0 0.32
elevated hematocrit 40.4%–51.9% (male)  
34.3%–45.2% (female)
1 (11) 0 0 0 0.40
elevated hOMa-r ≤1.6 2 (22) 2 (22) 1 (13) 2 (22) 0.95
Notes: Data shown as no. (%).
Abbreviations: a/g, albumin/globulin; aST, aspartate aminotransferase; BP, blood pressure; cPK, creatine phosphokinase; ggT, gamma-glutamyltransferase; hDl, high-
density lipoprotein; hOMa-r, homeostasis model assessment insulin resistance; lDl, low-density lipoprotein; WBc, white blood cell.
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